The Complement 3 Glomerulopathy Market is Expected to Gain Momentum during the Study ...

Retrieved on: 2021-01-13 13:30:00

Tags for this article:

Click the tags to see associated articles and topics

The Complement 3 Glomerulopathy Market is Expected to Gain Momentum during the Study .... View article details on hiswai:

Excerpt

Danicopan (Alexion Pharmaceuticals); Narsoplimab (Omeros Corporation); Pegcetacoplan (Apellis Pharmaceuticals); ChemoCentryx (Avacopan) ...

Article found on: www.prnewswire.com